RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its
First Quarter (Q1) 2011 financial results. These results have been prepared in
compliance with International Financial Reporting Standards (IFRS).


Total Sales hit a new record for a first quarter and were 54% higher at $478,295
in Q1 2011, compared to $310,956 in Q1 2010. The increase was driven primarily
by growth in the pharmaceutical segment of the business. The compound quarterly
growth rate for the company's pharmaceutical business over the past four
quarters has averaged 41%. Pharmaceutical business sales for Q1 2011 grew 297%
over Q1 2010 and grew 30% over Q4 2010.


Gross Margins increased from 65.0% in Q1 2010, to 73.4% in Q1 2011 primarily
because of mix in favour of higher margin products.


The Company improved its operating profit from a loss of ($50,354) in Q1 2010,
to an operating profit of $2,923 in Q1 2011, despite an increase in selling and
marketing expenditure of 134%. The Company incurred a total comprehensive loss
of ($886) in Q1 2011 versus a loss of ($50,907) in Q1 2010.


Full details of Q1 2011 results including March 31, 2011 Financial Statements
and Management's Discussion & Analysis will be posted on sedar.com on June 27,
2011.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024